Skip to main content

NASDAQ:SONN - Sonnet BioTherapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 393.83 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.62
▼ -0.07 (-4.14%)
1 month | 3 months | 12 months
Get New Sonnet BioTherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SONN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SONN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$8.00
▲ +393.83% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Sonnet BioTherapeutics in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 393.83% upside from the last price of $1.62.

Buy

The current consensus among 1 contributing investment analysts is to buy stock in Sonnet BioTherapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/15/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/11/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/9/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/7/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/8/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/3/2020Chardan CapitalBoost Price TargetPositive ➝ Buy$7.00 ➝ $8.00Medium
i
Rating by Keay Nakae at Chardan Capital
8/16/2020Chardan CapitalReiterated RatingBuy$7.00Low
i
Rating by Keay Nakae at Chardan Capital
6/25/2020Chardan CapitalReiterated RatingBuy$7.00Low
i
Rating by Keay Nakae at Chardan Capital
6/5/2020Chardan CapitalInitiated CoverageBuy$7.00High
i
Rating by K. Nakae at Chardan Capital
(Data available from 5/8/2016 forward)
Sonnet BioTherapeutics logo
Sonnet BioTherapeutics Holdings, Inc., an oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding (FHAB) technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate includes SON-080, a human version of low dose Interleukin-6 (IL-6), which has completed Phase I trials for the treatment of patients with chemotherapy-induced peripheral neuropathy. The company is also developing SON-081, a low dose IL-6 for the treatment of patients with diabetic peripheral neuropathy and is under phase I trials; SON-1010, a FHAB derived compound, which utilizes a human version of Interleukin-12 (IL-12) is under pre-clinical trial, as well as SON-1210, a bi-specific construct that combines FHAB with IL-12 and human Interleukin-15 for the treatment of solid tumor is under pre-clinical trial. In addition, it develops SON-2014, a bi-specific combination of granulocyte-macrophage colony stimulating factor and Interleukin-18 for the treatment of cancer; and SON-3015, a bi-specific combination of anti-IL6 and anti-tumor growth factor beta for tumor and bone metastases. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
Read More

Today's Range

Now: $1.62
$1.61
$1.72

50 Day Range

MA: $2.22
$1.69
$2.56

52 Week Range

Now: $1.62
$1.61
$7.89

Volume

1,293,753 shs

Average Volume

1,213,487 shs

Market Capitalization

$28.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.72

Frequently Asked Questions

What sell-side analysts currently cover shares of Sonnet BioTherapeutics?

The following Wall Street research analysts have issued research reports on Sonnet BioTherapeutics in the last year: Chardan Capital, and Zacks Investment Research.
View the latest analyst ratings for SONN.

What is the current price target for Sonnet BioTherapeutics?

1 Wall Street analysts have set twelve-month price targets for Sonnet BioTherapeutics in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 393.8%. Chardan Capital has the highest price target set, predicting SONN will reach $8.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $8.00 for Sonnet BioTherapeutics in the next year.
View the latest price targets for SONN.

What is the current consensus analyst rating for Sonnet BioTherapeutics?

Sonnet BioTherapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SONN will outperform the market and that investors should add to their positions of Sonnet BioTherapeutics.
View the latest ratings for SONN.

What other companies compete with Sonnet BioTherapeutics?

How do I contact Sonnet BioTherapeutics' investor relations team?

Sonnet BioTherapeutics' physical mailing address is 100 OVERLOOK CENTER SUITE 102, PRINCETON NJ, 08540. The company's listed phone number is 609-375-2227 and its investor relations email address is [email protected] The official website for Sonnet BioTherapeutics is www.chanticleerholdings.com.